New Anti-Metastatic Agent Adhibin Discovered: A Potential Game Changer in Cancer Treatment
/in Preclinical Research/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/in Artificial Intelligence, Preclinical Research/by MaxCRISPR Strikes Again: Fat Cells Starve Tumors,A Revolutionary Approach to Cancer Treatment
/in CRISPR, Preclinical Research/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/in Oncolytic, Preclinical Research/by MaxHarnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer
/in Preclinical Research, PROTACs/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025
